3-hydroxykynurenine has been researched along with Stroke in 2 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate if there is a correlation between serum kynurenines levels with poststroke anxiety and depression symptoms and disability scales." | 7.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "A cross-sectional case-control study was conducted in patients with first stroke, of >1 month and <1 year of evolution, with no history of previous psychiatric or neurological disorders; the Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), functional evaluations (Barthel index, Functional Independence Measure [FIM]) were applied and serum kynurenines (Kyns) were determined." | 7.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "The kynurenine pathway is a complex enzymatic cascade of tryptophan catabolism, generating various neuroactive metabolites." | 6.58 | Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects. ( Fülöp, F; Hertelendy, P; Toldi, J; Vécsei, L, 2018) |
| "Ischemic stroke is one of the leading causes of mortality and permanent disability in developed countries." | 6.58 | Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects. ( Fülöp, F; Hertelendy, P; Toldi, J; Vécsei, L, 2018) |
| "To investigate if there is a correlation between serum kynurenines levels with poststroke anxiety and depression symptoms and disability scales." | 3.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "A cross-sectional case-control study was conducted in patients with first stroke, of >1 month and <1 year of evolution, with no history of previous psychiatric or neurological disorders; the Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), functional evaluations (Barthel index, Functional Independence Measure [FIM]) were applied and serum kynurenines (Kyns) were determined." | 3.96 | Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study. ( Barajas-Martínez, K; Carrillo-Mora, P; Estrada-Cortés, B; Franyutti-Prado, K; Gamboa-Coria, G; Martínez-Cortéz, JA; Pérez-De la Cruz, V; Quinzaños-Fresnedo, J; Ramírez-Ortega, D; Ramos-Chávez, LA; Rangel-Caballero, F; Rodríguez-Barragán, M; Sánchez-Chapul, L; Sánchez-Vázquez, I; Toussaint-González, P, 2020) |
| "The kynurenine pathway is a complex enzymatic cascade of tryptophan catabolism, generating various neuroactive metabolites." | 2.58 | Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects. ( Fülöp, F; Hertelendy, P; Toldi, J; Vécsei, L, 2018) |
| "Ischemic stroke is one of the leading causes of mortality and permanent disability in developed countries." | 2.58 | Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects. ( Fülöp, F; Hertelendy, P; Toldi, J; Vécsei, L, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrillo-Mora, P | 1 |
| Pérez-De la Cruz, V | 1 |
| Estrada-Cortés, B | 1 |
| Toussaint-González, P | 1 |
| Martínez-Cortéz, JA | 1 |
| Rodríguez-Barragán, M | 1 |
| Quinzaños-Fresnedo, J | 1 |
| Rangel-Caballero, F | 1 |
| Gamboa-Coria, G | 1 |
| Sánchez-Vázquez, I | 1 |
| Barajas-Martínez, K | 1 |
| Franyutti-Prado, K | 1 |
| Sánchez-Chapul, L | 1 |
| Ramírez-Ortega, D | 1 |
| Ramos-Chávez, LA | 1 |
| Hertelendy, P | 1 |
| Toldi, J | 1 |
| Fülöp, F | 1 |
| Vécsei, L | 1 |
1 review available for 3-hydroxykynurenine and Stroke
| Article | Year |
|---|---|
Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects.
Topics: Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Quinolinic Acids; Receptors, | 2018 |
1 other study available for 3-hydroxykynurenine and Stroke
| Article | Year |
|---|---|
Serum Kynurenines Correlate With Depressive Symptoms and Disability in Poststroke Patients: A Cross-sectional Study.
Topics: Adult; Aged; Case-Control Studies; Cross-Sectional Studies; Depression; Female; Functional Status; H | 2020 |